FIELD: medicine.
SUBSTANCE: invention relates to an application of a composition comprising a polypeptide consisting of SEQ ID NO: 1 (EARPALLTSRLRFIPK (GV1001)) for producing a medicinal product for preventing suppression of the immune function caused by treatment of pancreatic cancer, wherein the composition is administered simultaneously with a chemotherapeutic agent, wherein the chemotherapeutic agent constitutes gemcitabine, capecitabine, or a combination thereof, and the composition does not reduce the level of one or more cytokines selected from the group consisting of IL1β, IL-1ra, IL-2, IL-4, IL-5, IL-7, IL-10, IL-12, IL-13, IL-17, GCSF, IFNγ, eotaxin, MIP1β, RANTES and TNFα, in the serum. Also proposed is an application of the set for preventing suppression of the immune function caused by anticancer treatment of pancreatic cancer, including a polypeptide defined in claim 1 and a chemotherapeutic agent, wherein the chemotherapeutic agent constitutes gemcitabine, capecitabine, or a combination thereof.
EFFECT: application of a polypeptide composition for preventing suppression of the immune function caused by treatment of pancreatic cancer.
6 cl, 25 dwg, 6 tbl, 1 ex
